Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus.

Autor: Cazarim MS; Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Brazil. Electronic address: mscazarim@usp.br., da Cruz-Cazarim ELC; Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Brazil. Electronic address: estaelcruz@fcfrp.usp.br., Baldoni AO; Federal University of São João Del-Rei (UFSJ), Brazil. Electronic address: andrebaldoni@ufsj.edu.br., Dos Santos TBE; Federal University of São João Del-Rei (UFSJ), Brazil. Electronic address: enesthais@gmail.com., de Souza PG; Federal University of São João Del-Rei (UFSJ), Brazil. Electronic address: paula.gsouza@hotmail.com., Silva IA; Federal University of São João Del-Rei (UFSJ), Brazil. Electronic address: ingrid-almeida@hotmail.com., Rodrigues RNR; Federal University of São João Del-Rei (UFSJ), Brazil. Electronic address: robertaniriam@gmail.com., Maia ACFC; Federal University of São João Del-Rei (UFSJ), Brazil. Electronic address: aldinhamaia@hotmail.com., Pereira LRL; Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Brazil. Electronic address: lpereira@fcfrp.usp.br., Sanches C; Federal University of São João Del-Rei (UFSJ), Brazil. Electronic address: csanches@ufsj.edu.br.
Jazyk: angličtina
Zdroj: Diabetes & metabolic syndrome [Diabetes Metab Syndr] 2017 Dec; Vol. 11 Suppl 2, pp. S859-S865. Date of Electronic Publication: 2017 Jul 03.
DOI: 10.1016/j.dsx.2017.07.006
Abstrakt: Introduction: Type 2 diabetes mellitus (T2DM) has burdened health systems in the world to the value of 500 billion dollars/year. Dipeptidyl peptidase 4 inhibitors (DPP-4 Inhibitors) have been strongly associated with spending on the treatment of T2DM by the courts in Brazil. The aim of this study was to estimate the most cost-effective DPP-4 Inhibitor for T2DM treatment. A pharmacoeconomic study of cost-effectiveness was performed in a medium-sized municipality in Minas Gerais state, Brazil.
Methods: The data are from legalization in municipal health in 2013. The effectiveness of DPP-4 Inhibitors was measured by the reduction in glycated hemoglobin (A1c). The direct medical costs of drug and adverse drug reactions were identified. With these data, a cost-effectiveness ratio (CER) and construction of the decision tree for sensitivity analysis were performed.
Results: The representative of the most effective in reducing A1c gliptins was sitagliptin in combination with metformin, it was able to reduce A1c by 1.16% (1.09 to 1.22, CI 95%). The drug with the lowest cost was linagliptin, with a cost per patient/year of US$ 481.42. Sensitivity analysis performed by the decision tree shows that sitagliptin in association with metformin had the CER of US$ 1,506.75 per patient/year, to reduce A1c by 1%.
Conclusion: The most cost-effective DPP-4 Inhibitor was sitagliptin with metformin.
(Copyright © 2017 Diabetes India. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: